Physician profile
Ryan A Yates
NPI 1770870289
$19,782.96
in general payments reported to CMS, 2019-2025
76 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,423 · 2020: $1,687 · 2021: $2,169 · 2022: $2,730 · 2023: $4,352 · 2024: $3,160 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,760.55 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $1,726.27 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $1,603.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,189.98 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $1,145.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,095.38 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Astrazeneca Pharmaceuticals LP | $899.70 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $814.95 | 2019-2025 | Erleada, Darzalex, Balversa |
| Amgen INC. | $778.94 | 2019-2023 | Blincyto, Nplate, Xgeva |
| Gilead Sciences, INC. | $680.62 | 2022-2025 | Trodelvy |
| Celgene Corporation | $621.81 | 2019-2025 | Reblozyl, Pomalyst, Breyanzi |
| Lilly USA, LLC | $614.59 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Astellas Pharma US INC | $610.53 | 2019-2025 | Xtandi, Vyloy, Xospata |
| Abbvie INC. | $576.86 | 2019-2025 | Venclexta |
| Takeda Pharmaceuticals U.S.A., INC. | $516.05 | 2019-2025 | Ninlaro, Iclusig, Alunbrig |
| Glaxosmithkline, LLC. | $484.34 | 2020-2025 | Zejula, Jemperli, Ojjaara |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Yates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.